About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

[18F]ACI-19626 PET in TDP-43 Proteinopathies | Clinical Trials | Clareo Health

RECRUITINGEARLY Phase 1

[18F]ACI-19626 PET in TDP-43 Proteinopathies

Phase 1 Study to Evaluate [18F]ACI-19626 as a Potential PET Radioligand for Imaging TDP-43 Inclusions in the Brain of Patients With Suspected TDP-43 Proteinopathies Compared With Healthy Controls

NCT06891716•AC Immune SA

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Frontotemporal Dementia (FTD)Amyotrophic Lateral Sclerosis (ALS)TDP-43 Proteinopathies+2 more

Interventions

[18F]ACI-19626

Locations

1

Netherlands

Locations (1)

Amsterdam UMC

Amsterdam, Netherlands

Key Dates

Start Date

January 21, 2025

Primary Completion Date

November 1, 2026

Completion Date

November 1, 2026

Last Updated

March 24, 2025

Related Studies

Retinal Imaging in Neurodegenerative Disease

NCT03233646

Alzheimer's DiseaseMild Cognitive Impairment+13 more

Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.

NCT07187388

Amyotrophic Lateral Sclerosis (ALS)Primary Lateral Sclerosis (PLS)+1 more

Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging

NCT07202494

Multiple SclerosisNeuromyelitis Optica Spectrum Disorders+8 more

GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices

NCT07127172

Tetraplegia/TetraparesisQuadriplegia+7 more

UAE-PRIME: A Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices

NCT06992596

Tetraplegia/TetraparesisQuadriplegia+7 more

RECRUITINGEARLY Phase 1

A Study to Evaluate the Tolerability, Safety and Efficacy of VGN-R13 in Patients with ALS

NCT06849609

Amyotrophic Lateral Sclerosis (ALS)

View all related studies

Sponsors

Lead Sponsor

AC Immune SA

Collaborators

Amsterdam UMC, location VUmc

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 24, 2025Data synced to Clareo: April 27, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions